Upadacitinib (new indication: Crohn's disease, pretreated patients)

Subject:

• Active Substance: Upadacitinib
• Name: Rinvoq®
• Therapeutic area: Crohn's disease 
• Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG

Time table:

• Start: 01.05.2023
• Publication of assessment: 01.08.2023
• End of public hearing: 22.08.2023
• Final decision by G-BA: middle of October 2023

Comparative therapy:

1. Patients who have had an inadequate response, no longer respond, or have demonstrated intolerance to conventional therapy:

   - TNF-α antagonist (adalimumab or infliximab) OR
   - integrin inhibitor (vedolizumab) OR
   - interleukin inhibitor (ustekinumab)

2. Patients who have had an inadequate response, no longer respond, or have demonstrated intolerance to a biologic (TNF-α antagonist or integrin inhibitor or interleukin inhibitor): A change in therapy to ​​​​​​​

   - TNF-α antagonist (adalimumab or infliximab) OR
   - integrin inhibitors (vedolizumab) OR
   - interleukin inhibitors (ustekinumab)